Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report
Ticker: PRNAF · Form: 6-K · Filed: Apr 30, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, cash-flow, registration-statement
TL;DR
Alterity Therapeutics filed a 6-K with a cash flow report, check it out.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on April 30, 2024, incorporating by reference its Quarterly Activities/Appendix 4C Cash Flow Report. This filing is part of ongoing registration statements on Form S-8 and Form F-3, indicating continued efforts to manage and potentially expand its securities offerings.
Why It Matters
This filing provides an update on Alterity's financial activities and cash flow, which is crucial for investors to assess the company's operational status and funding needs.
Risk Assessment
Risk Level: medium — As a development stage enterprise in the pharmaceutical sector, Alterity Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- April 30, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
- Appendix 4C Cash Flow Report (document) — Included exhibit
FAQ
What is the purpose of incorporating this 6-K into existing registration statements?
The 6-K is incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 and Form F-3, suggesting it contains information relevant to the ongoing registration or offering of securities.
What specific financial information is provided in the incorporated Appendix 4C Cash Flow Report?
The filing explicitly states that Exhibit 99.1 is the 'Quarterly Activities/Appendix 4C Cash Flow Report,' indicating it details the company's cash flow activities for the relevant quarter.
When was Alterity Therapeutics Limited previously known by another name?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Where is Alterity Therapeutics Limited's principal executive office located?
The principal executive office of Alterity Therapeutics Limited is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Yes, Alterity Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-04-30 08:00:04
Filing Documents
- ea0204954-6k_alterity.htm (6-K) — 14KB
- ea020495401ex99-1_alterity.htm (EX-99.1) — 109KB
- ex99-1_001.jpg (GRAPHIC) — 54KB
- ex99-1_002.jpg (GRAPHIC) — 4KB
- ex99-1_003.jpg (GRAPHIC) — 1KB
- 0001213900-24-037462.txt ( ) — 205KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Quarterly Activities/Appendix 4C Cash Flow Report 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: April 30 , 2024 2